Clinical data
ATC code G04BE11 (WHO)
Pharmacokinetic data
Biological half-life 7.3–12.1 hours
CAS Number 268203-93-6 N
PubChem (CID) 6918523
DrugBank DB06267 YesY
ChemSpider 5293720 YesY
KEGG D10027 N
Chemical and physical data
Formula C25H36N6O4S
Molar mass 516.657 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

The drug udenafil, marketed under the trade name Zydena, is within the PDE5-inhibitor class (which also includes avanafil, sildenafil, tadalafil, and vardenafil). Used, like other PDE5 inhibitors, to treat erectile dysfunction, undenafil was developed by Dong-A Pharmaceutical.[1] With action of fairly rapid onset (peak plasma concentration after 1 to 1.5 hours) yet long duration (plasma half life of 11 to 13 hours), udenafil's pharmacokinetics allows once-daily dosage (in addition to on-demand use).[2] Typical doses are 100 and 200 mg. Udenafil is available in Korea, Russia, and the Philippines;[3] in the United States, it has not been approved by the U.S. Food and Drug Administration.


  1. Zydena (udenafil) product-information page. Dong-A Pharmaceutical. Retrieved on April 13, 2009.
  2. "Udenafil: Efficacy and tolerability in the management of erectile dysfunction".
  3. [http://www.drugs.com/international/zydena.html "Zydena", Drugs.com

This article is issued from Wikipedia - version of the 4/17/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.